Ulcerative colitis treatment begins with a definitive diagnosis and a determination of the severity of illness. Once this initial diagnosis has been made, the immediate goal of treatment is to reduce the painful physical symptoms associated with it. Since there is no cure for ulcerative colitis, the long-term goal of treatment is to prevent future onset of illness, or relapse.

Both ulcerative colitis, and a related disorder called Crohn’s Disease, are characterized by an abnormal immune system response within the intestines. In patients with ulcerative colitis, the location of this response is restricted to the large intestine, or colon. The resulting inflammation and ulceration of the intestinal walls can cause abdominal discomfort, diarrhea, and rectal bleeding, the main symptoms of ulcerative colitis.

Due to the fact that other health conditions may exist that exhibit similar symptoms, care for ulcerative colitis begins with a confirmation of this initial diagnosis. This includes taking stool samples to rule out the presence of parasites or an existing infection within the colon, and performing blood tests to detect elevated white blood cell counts (high white blood cell counts indicate that the cause of inflammation is due to the activation of the body’s own immune response).

A visual examination, either directly using a sigmoidoscope or a colonoscope, or indirectly via a barium enema, will help make the final confirmation that colitis is in fact the culprit. These visualization techniques are an essential step in ulcerative colitis treatment because they allow the physician to measure the severity of the illness, and therefore to figure out the best course to minimize the symptoms of ulcerative colitis.

Medications play a large part in both the initial treatment and long-term care for ulcerative colitis. These medications fall into two main categories: immunomodulators, which alter the proteins produced by the immune system which cause inflammation, and anti-inflammatory medications, which act to reduce the inflammation directly. Although these medications do not cure ulcerative colitis, they can induce remission of its symptoms and lengthen the time between relapses. As such they offer an ulcerative colitis treatment option that many sufferers take advantage of.

In addition to helping manage mild to moderate UC flares, Asacol (mesalamine) helps relieve ulcerative colitis symptoms including number of bowel movements and rectal bleeding as early as 3 weeks. Asacol is the only sulfa-free 5-ASA medication indicated for both treatment of mild to moderate flare-ups of ulcerative colitis and maintenance of remission of ulcerative colitis. Asacol HD (mesalamine) delayed-release tablets are available only by prescription for the treatment of moderately active UC.

Asacol and Asacol HD are generally well tolerated. In clinical studies, some patients taking Asacol or Asacol HD reported upset stomach, diarrhea, stomach pain, belching, flatulence, worsening of UC symptoms, headache, runny nose, sore throat, and general pain. If you want to learn more information, please visit Asacol.com. They will help you understand what ulcerative colitis is and the various aspects of the condition, including treatment, diet, and maintenance therapy.

If you are experiencing any of the symptoms of ulcerative colitis mentioned above, make sure you visit your doctor right away for a thorough examination. If you do have this disorder, your doctor will help you determine the best ulcerative colitis treatment for your particular case.

CAPS (cryopyrin-associated periodic syndrome) is a group of rare genetic diseases that can cause rashes, fevers, joint pain, and other inflammatory symptoms. These symptoms often occur after exposure to cold or damp air or a drop in temperature, but symptoms may also show up for no clear reason. Cryopyrin is a protein responsible for triggering the inflammation and painful symptoms of CAPS. A malfunction in this protein is what these diseases have in common. Three syndromes comprise CAPS: Familial Cold Auto-inflammatory Syndrome (FCAS), (previously termed Familial Cold Urticaria), Muckle-Wells Syndrome (MWS) and Neonatal-Onset Multisystem Inflammatory Disease (NOMID), which also is referred to as Chronic Infantile Neurologic Cutaneous Articular Syndrome (CINCA).

Familial Cold Autoinflammatory Syndrome is the most common and least severe type.
* Symptoms: Rash, headache, fever, feeling tired, sore or red eyes, and muscle or joint pain
* Onset of symptoms: At birth or, rarely, later in childhood
* Trigger of symptoms: Exposure to cold temperature
* Duration of symptoms: Typically last no more than 24 hours

Muckle-Wells Syndrome is more severe than FCAS.
* Symptoms: Those symptoms listed above, as well as loss of hearing. High protein levels are detected during screening and are a sign of the disease
* Onset of symptoms: At birth or, rarely, later in childhood
* Trigger of symptoms: Exposure to cold temperature, weakness of the body, or other reasons that are not yet known
* Duration of symptoms: Usually last between 1 and 3 days

Neonatal-Onset Multisystem Inflammatory Disease is the most severe type.
* Symptoms: All of the above mentioned symptoms, as well as loss of eyesight, swelling of the knees, and mental disability
* Onset of symptoms: Almost always at birth
* Trigger of symptoms: Reasons that are not yet known
* Duration of symptoms: Continuous with symptoms worsening from time to time

Diagnosis of CAPS is often missed due to the rarity of these conditions (low index of suspicion). Furthermore, some symptoms of CAPS may be similar to findings of more common diseases such as systemic JIA and systemic lupus erythematosus. Some features of FCAS may be mistaken for Acquired Cold Urticaria (ACU), a more prevalent condition. Both demonstrate cold-induced rash; however, in ACU, the rash is usually localized to sites of direct cold exposure, whereas in FCAS, the inflammation is more generalized, being systemic in nature.

Cryopyrin-Associated Periodic Syndromes are a rare and newly discovered group of autosomal-dominant disorders that can best be diagnosed through analysis of family history, compilation of clinical history, including age of primary presentation and frequency/duration of episodes, physical examination, laboratory and histological testing, and genetic analysis. Not all CAPS patients have detectable genetic mutations.

Are you or other family members troubled by recurring rashes, fevers, aching joints, and other symptoms? It’s time to take action. Learn about CAPS – Cryopyrin-Associated Periodic Syndromes, a group of rare genetic diseases that runs in families and can be passed down through generations at CapsFamilyConnections.com. Take a few minutes to complete the screener. Your answers can help you take a more active role in your medical care, and that of others.